Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Platelet-Rich Plasma from Two Different Systems in Knee Osteoarthritis

Official title: Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems

Run by University of California, San Francisco · NCT07491367 · Data updated 2026-11-12

This study compares PRP made by two FDA-approved machines to see if the platelets differ and whether injections help knee symptoms.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorUniversity of California, San Francisco
Academic / other
Drugs / interventionschemotherapy, prednisone
Locations1 site (San Francisco, California)
StatusRecruiting
StartedSeptember 1, 2026
Main results expectedSeptember 2028
Study endsSeptember 2028
Registry record updatedAugust 18, 2026
Trial IDNCT07491367 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with Kellgren-Lawrence grade 1–3 knee osteoarthritis, at least 3 months of knee symptoms, and ability to complete physical therapy.

Probably not a fit

Individuals with advanced knee arthritis, recent knee injections, or conditions excluding PRP therapy may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 interventional study evaluates differences in the quality of platelet-rich plasma produced by two commercial systems in adults with knee osteoarthritis. Participants will receive PRP prepared with either the APEX Biologix XCELL PRP System or the Emcyte PurePRP system, and outcomes on knee symptoms will be tracked after injection. The study also examines whether the two preparation methods yield PRP with different platelet counts or functional properties. Eligibility includes adults with KL grade 1–3 OA, persistent knee symptoms, and ability to participate in physical therapy. Exclusion criteria cover recent injections, prior knee surgeries, bleeding disorders, immunocompromise, active cancer, and other knee-affecting conditions.

Why it matters

Potential benefit: Participants may experience symptom relief from PRP injections, and the study may clarify whether one system produces higher-quality PRP leading to better outcomes.

How similar studies have gone: Previous work suggests PRP quality and preparation method can influence outcomes, but direct head-to-head comparisons like this are less common.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Kellgren-Lawrence (KL) Grade 1-3 knee osteoarthritis
* Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee
* Will be able to attend and perform physical therapy

Exclusion Criteria:

* Received injection therapy for knee osteoarthritis in the past 6 months
* Have severe arthritis diagnosed in ≥1 major joint by radiology criteria
* History of septic arthritis
* Underwent knee surgery for osteoarthritis or osteochondral defects within 1 year before randomization (e.g., autograft or allograft surgery)
* Have had high tibial osteotomy, partial knee replacement, patellar resurfacing, total knee replacement, or have existing surgical hardware in the knee
* Received a platelet-rich plasma injection elsewhere in the body within the past 3 months
* Have a platelet disorder or bleeding disorder
* Have a rheumatologic disease, autoimmune disorder, immunocompromised status, or active history of cancer
* Are taking chemotherapy, require regular prednisone, or require regular anti-inflammatory use
* Are pregnant, breastfeeding, or unwilling to practice birth control during the study
* If both knees have osteoarthritis and the other knee has KL score equal to or greater than 2.
* Have uncontrolled illness, physical disability, or other contraindication to aerobic exercise training

Where it's running

  • University of California San Francisco
    San Francisco, California, United States
    Recruiting

Study contacts

  • Principal investigator: Anthony Luke, MD — University of California, San Francisco
  • Study coordinator: Joel Kopcow
  • Email: joel.kopcow@ucsf.edu
  • Phone: 970-590-0314

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.